Drug Trial Radar · NCT06279286
Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder
Last checked: Nov 19, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
312
Planned (sponsor's estimate)
Start
May 2024
Primary completion
Jan 2025
Study completion Jan 2025
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this phase Ⅰb/Ⅱ study is to investigate the safety, tolerability, pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) after multiple dose administration and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) measured by polysomnography (PSG) in Chinese adult participants with insomnia disorder.
Conditions
- Insomnia Disorder
Interventions
HS-10506Drug
HS-10506, tablets (10mg, 20mg, 40mg and 80mg) at night once daily from Day 1 to Day 5 in phase Ib study, and from Day 1 to Day 28 in phase II study.
PlaceboDrug
Placebo, placebo tablets matching the HS-10506 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AE)Time frame: Baseline up to the end of the study (3 days after the last dose) or early withdrawal
- Incidence and severity of serious adverse events (SAE)Time frame: Baseline up to the end of the study (3 days after the last dose) or early withdrawal
- Changes in laboratory test before and after drug administrationTime frame: Baseline up to the end of the study (3 days after last dose) or early withdrawal
- Changes in ECG before and after drug administrationTime frame: Baseline up to the end of the study (3 days after last dose) or early withdrawal
- Changes in Karolinska Sleepiness Scale (KSS) scores before and after drug administrationTime frame: From start of the drug administration to the next day of the last dose or early withdrawal
- Change from baseline in the mean LPS measured by PSG on Night 13 and Night 14Time frame: Baseline, Night 13& Night 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xuanwu Hospital Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.